Development and pre-clinical evaluation of G-DSF inhibitors for inflammatory joint disease

G-CSF最初被认为是一种调节骨髓中性粒细胞和造血干细胞产生的细胞因子，目前在世界各地的骨髓移植患者中用于临床。最近，应用肿瘤坏死因子拮抗剂的抗细胞因子治疗已被引入类风湿关节炎的治疗。然而，并不是所有的患者都对肿瘤坏死因子抑制有反应。我们收集了大量的数据，表明在炎性关节疾病的实验模型中，G-CSF也促进炎症。我们建议开发G-CSF的抑制剂作为一种新的形式的抗细胞因子治疗炎性关节疾病，如类风湿性关节炎。

G-CSF was originally identified as a cytokine regulating the production of neutrophils and haemopoietic stem cells from the bone marrow and it is currently used clinically for these properties in bone marrow transplant patients around the world. Anti-cytokine therapy with TNF blockade has recently been introduced for the treatment of rheumatoid arthritis. However, not all patients respond to TNF inhibition. We have gathered extensive data which shows that G-CSF also promotes inflammation in experimental models of inflammatory joint disease. We propose to develop inhibitors of G-CSF as a novel form of anti-cytokine therapy for inflammatory joint disorders, such as rheumatoid arthritis.